A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
company business-strategic decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2024 | estimated | When the study began enrolling |
| Primary completion | 2025-10-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-17 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-02-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pediatric Growth Hormone Deficiency
Intervention
- Device: Sharps bin to collect used needles/injections
Primary outcome
what the primary-completion date above is the date OFMean Adherence To Ngenla and daily growth hormone
measured 12 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed